At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
Fluzone: Influenza virus vaccine +1 morebiological
Likely dose
Fluzone: Influenza virus vaccine 0.1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age
In Brief
A Phase 2 clinical trial evaluating Fluzone: Influenza virus vaccine for Influenza. Completed, enrolled 110 participants across 2 sites.
Detailed Summary
To describe any degree of preference for the route of administration of Fluzone influenza vaccine, ID versus IM, in healthy adult subjects 18-49 years of age. To collect safety data, injection site reactions, and systemic reactions, through Day 7 post-vaccination; SAEs through day 28 post-vaccination
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionMay 2008
Study CompletionJun 2008
TodayJul 2026
First PostedFeb 25, 2008
Enrollment StartJan 1, 2008
Primary CompletionMay 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.4 years ago
Interventions
Fluzone: Influenza virus vaccinebiological
0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
Fluzone: Influenza virus vaccinebiological
0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid